Summary Pharmaceuticals in Singapore industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2011-15, and forecast to 2020). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Findings Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in Singapore
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Singapore
Leading company profiles reveal details of key pharmaceuticals market players' global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the Singapore pharmaceuticals market with five year forecasts
Synopsis Essential resource for top-line data and analysis covering the Singapore pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Reasons To Buy What was the size of the Singapore pharmaceuticals market by value in 2015?
What will be the size of the Singapore pharmaceuticals market in 2020?
What factors are affecting the strength of competition in the Singapore pharmaceuticals market?
How has the market performed over the last five years?
Who are the top competitors in Singapore's pharmaceuticals market?
Key Highlights The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare. Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors). Any currency conversions used in the production of this report have been calculated at constant 2015 annual average exchange rates.
The Singaporean pharmaceuticals market had total revenues of $825m in 2015, representing a compound annual growth rate (CAGR) of 9.2% between 2011 and 2015.
Total healthcare expenditure is expected to continue to grow very rapidly and has already increased almost 300% over the past decade, second only to Japan in the Asian-Pacific region.
The performance of the market is forecast to decelerate, with an anticipated CAGR of 6.1% for the five-year period 2015 - 2020, which is expected to drive the market to a value of $1.1bn by the end of 2020.
Table Of Contents
Pharmaceuticals in Singapore Table of Contents Executive Summary Market value Market value forecast Geography segmentation Market share Market rivalry Market Overview Market definition Market analysis Market Data Market value Market Segmentation Geography segmentation Market share Market Outlook Market value forecast Five Forces Analysis Summary Buyer power Supplier power New entrants Threat of substitutes Degree of rivalry Leading Companies GlaxoSmithKline Plc Novartis AG Pfizer Inc. Macroeconomic Indicators Country data Methodology Industry associations Related MarketLine research Appendix About MarketLine
List of Figures Figure 1: Singapore pharmaceuticals market value: $ billion, 2011-15 Figure 2: Singapore pharmaceuticals market geography segmentation: % share, by value, 2015 Figure 3: Singapore pharmaceuticals market share: % share, by value, 2015 Figure 4: Singapore pharmaceuticals market value forecast: $ billion, 2015-20 Figure 5: Forces driving competition in the pharmaceuticals market in Singapore, 2015 Figure 6: Drivers of buyer power in the pharmaceuticals market in Singapore, 2015 Figure 7: Drivers of supplier power in the pharmaceuticals market in Singapore, 2015 Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Singapore, 2015 Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in Singapore, 2015 Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in Singapore, 2015 Figure 11: GlaxoSmithKline Plc: revenues and profitability Figure 12: GlaxoSmithKline Plc: assets and liabilities Figure 13: Novartis AG: revenues and profitability Figure 14: Novartis AG: assets and liabilities Figure 15: Pfizer Inc.: revenues and profitability Figure 16: Pfizer Inc.: assets and liabilities